CD20 MicroBeads were developed for positive selection or depletion of human CD20+ B cells from different cell sources such as human PBMCs, bone marrow, cell cultures or lymphoid tissues.
Related products for CD20 MicroBeads, human
B cells were separated from PBMCs using CD20 MicroBeads and the autoMACS™ Separator.
CD20 MicroBeads were developed for positive selection or depletion of human CD20+ B cells from different cell sources such as human PBMCs, bone marrow, cell cultures or lymphoid tissues.
CD20 is a non-glycosylated transmembrane protein of 33–37 kDa that becomes heavily phosphorylated upon activation1,2. It is expressed exclusively on B cells, including pre-B cells, naive, mature, and activated B cells, B cell blasts, and the majority of malignant B cells, but not on early B cell progenitors or plasma cells2,3.
Purified CD20+ B cells may be used in cell biological studies, such as analysis of signal transduction, chemotaxis, allergen response, apoptosis, or in molecular studies, e.g., subset-specific microarrays.
For positive selection: MS, LS, XS, or autoMACS® Columns. For depletion: LD, D, or autoMACS Columns.
- Chang et al. (1996) Appl. Immunohistochem. 4: 1-15
- Cragg, M. S. et al. (2002) Opposing properties of CD20 mAb. In: Leucocyte typing VII, Oxford University Press.
- Polyak et al. (2002) CD20 Workshop Panel report. In: Leucocyte typing VII, Oxford University Press.
- Countouriotis, A. et al. (2002) Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 20: 215-229
You have previously chosen International as your location.
What do you want to do?